There are many compelling reasons in favor of XEME’s products when compared with active immunotherapies, such as dendritic cell (DC) vaccines:

​

1. XEME’s Aggregon® vaccine incorporates all essential attributes shown by science for a successful standard vaccine: microbial dimension to stimulate DC cells, IL-2 to expand and activate the anti-tumor killer cells, intact tumor antigens in their natural state, incorporation of all tumor antigens to reduce the chance of tumor escape, slow release of antigen and immune stimulator (IL-2) active ingredient, proper configuration (at the surface of Aggregon®) of both IL-2 and antigen for proper signaling and versatility of vaccine design.

2. XEME's vaccines are manufactured in about 8 hours, which is more than 10 times faster than DC vaccines and most other types of therapeutic cancer vaccines. This feature streamlines manufacture, increases the efficiency of production and reduces significantly the regulatory and cost burden.

3. Unlike vaccines composed of living dendritic cells that require highly specialized conditions and precautions, XEME’s vaccines are produced by a simple standard-controlled manufacturing process.

4. XEME’s vaccines are administered subcutaneously, which is much more convenient than intravenous infusion of dendritic cell vaccines and does not require repeated leukapheresis to provide starting material from the patient.

5. Unlike vaccines that “educate” dendritic cells “in vitro”, XEME vaccines educate the dendritic cells “in vivo”. In addition, XEME's vaccine stimulates the effector arm of the immune system (anti-tumor killer cells) through display and slow release of its IL-2 component.

6. The unique, rapid (8 hrs) manufacturing feature of XEME's vaccines will allow novel modalities of treatment (“prime-boost”) that can be integrated with chemotherapy and other therapeutic interventions.

​

XEME’s unique, disruptive, and patented technology platform has the following competitive advantages: